Cantargia AB Briefing on Update Recently Announced Rights Issue Transcript
Good morning and welcome to the Cantargia Shareholder Briefing on Rights Issue. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the Cantargia website following the conclusion of the event.
I'd now like to turn the call over to Dr. Göran Forsberg, Chief Executive Officer of Cantargia. Please go ahead, Göran.
¶ -
[Thank you so much.] It's a pleasure to have you all attending this briefing ahead of our proposed drug rights issue, and I will take you a little bit through this rights issue, why we're doing it, and let's say, where we come from. I really think we come from a position of strength here and moving forward.
So the background is very much that we presented new very exciting results using our lead asset, nadunolimab, at the international ASCO conference earlier on in June.
And we obviously realized that this presentation gave very increased international
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
